This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
LESI | Print Page | Sign In | Join
New York City
Group HomeGroup Home Blog Home Group Blogs
Search all posts for:   


View all (1) posts »

Panel Discussion: The Future of Healthcare

Posted By Administrator, Monday, March 20, 2017

NYC Chapter Panel Discussion:

A New President, A Brand New Environment:
What Does it Mean for our Healthcare Industry?

In early March, the LES NYC Chapter held a lively discussion about what could be coming in the healthcare industry under the new administration.  The discussion focused on three topics: IP, biotech funding, and pricing. While it was acknowledged that no one can predict anything under the current administration, positive and negative scenarios were explored.

Moderator: Christine Fischette
Panelists: T. Alexander Puutio, Carlo Rizzuto, Ed Saltzman 

For IP, discussion centered on what was not communicated in the debates where both parties took a stand against the Trans Pacific Partnership, TPP. Missed opportunities included transplanting best practices, harmonizing regulations and processes, endorsement of a common patent language, patent prosecution highways, quotas and tariffs, local costs and requirements for developing/launching/commercializing therapeutics, market access, market exclusivity, positioning of US as a leader in these complex negotiations, where Japan and Australia are now taking the lead.

Panelist Ed Saltzman standing with Kim Chotkowski, LES CEO

For biotech funding, discussion highlighted around the potential decrease in regulation, stimulation of business and more money available for investing in a strong market.

For pricing of pharmaceuticals, especially innovative, value-creating scenarios, such as real “cures” re: one administration of gene modifying therapeutics, or drugs with significant positive patient outcomes, including cancer medications in combination, the jury is still out on how best to pay for that value without “breaking the budgets” of payers. Positive, negative and no effect scenarios were discussed in terms of allowing Medicare to negotiate drug prices ranging from it will lower costs, it won’t matter because PBM’s negotiate prices anyway with pharma players, it will destroy the pricing of pharmaceuticals, as we know it.

Attendees: Linda Fort, Sapna Palla, Moderator: Christine Fischette 

All in all a lively discussion!  We are grateful to our panelists and moderator for a successful event and to our sponsor, Fox Rothschild, LLP, for their generosity.


This post has not been tagged.

Share |
Permalink | Comments (0)


Connect with more than 500 intellectual capital management decision-makers and thought leaders around the world. Join us at the LES 2019 Annual Meeting as a sponsor to promote your company and discover new business opportunities. Learn more
11130 Sunrise Valley Drive, Suite 350 Reston, VA 20191 Phone: 703-234-4058 Fax: 703-234-4147